The Hydroxyurea Absorption Phenotype: A Key PK/PD Determinant in Sickle Cell Disease Treatment
Amelia-Naomi Sabo, Charlotte Nazon, Catherine Paillard, Véronique Kemmel · 2026
Read The Hydroxyurea Absorption Phenotype: A Key PK/PD Determinant in Sickle Cell Disease Treatment by Amelia-Naomi Sabo, Charlotte Nazon, Catherine Paillard, Véronique Kemmel (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13305921.txt.
Description
Amelia-Naomi Sabo and co-authors model how hydroxyurea moves through the body in sickle cell disease in a 2026 analysis of trial data. Plasma samples came from 22 patients, mostly children, taking a daily oral dose. Response to the drug varies widely between patients, and the team looked for traits that explain that spread.
Two absorption patterns emerged: rapid absorbers reached higher peak levels than slow absorbers, although total exposure was similar. The absorption pattern explained about half of the variation in absorption rate between patients. Rapid absorbers also showed stronger gains in red cell size and fetal haemoglobin trends, without added toxicity signals. The authors propose adding absorption pattern to dosing algorithms so treatment can be tuned earlier for each patient.
Catalog record
| CREATOR | Amelia-Naomi Sabo, Charlotte Nazon, Catherine Paillard, Véronique Kemmel |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |